Dutasteride CAS 164656-23-9 EINECS NO 638-758-5

Product Description:

Product Name: Dutasteride CAS NO: 164656-23-9

Synonyms:

(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-Bis(trifluoroMethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-diMethyl-2-oxo-1H-Indeno[5,4-f]quinoline-7-carboxaMide;

(5α,17β)-;(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-Bis(trifluoroMethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-diMethyl-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxaMide-13C6;

6β-HydroxyDutasteride;4-Azaandrost-1-ene-17-carboxaMide,N-[2,5-bis(trifluoroMethyl)phenyl]-3-oxo-, (5a,17b)-;

Chemical & Physical Properties:

Appearance: White crystalline powder

Assay :≥99.00%

Density: 1.303 g/cm3

Boiling Point: 620.3℃ at 760 mmHg

Melting Point: 242-250℃

Flash Point: 329℃

Refractive Index: 1.523

Vapor Pressure: 0mmHg at 25℃

Safety Information:

HS Code: 2942000000

Dutasteride (INN, USAN, BAN, JAN) (brand name Avodart), developed by GlaxoSmithKline, is a triple 5α-reductase inhibitor that inhibits conversion of testostero-ne to dihydrotestostero-ne (DHT). It is used to treat benign prostatic hyperplasia. It increases the risk of erectile dysfunction and decreased sexua-l desire. Dutasteride (GG745) is a potent inhibitor of both 5 alpha-reductase isozymes. Dutasteride may possess off-target effects on the andro-gen receptor (AR) due to its structural similarity to DHT.IC50 Value:Target: 5 alpha-reductasein vitro: Dutasteride inhibited (3)H-T conversion to (3)H-DHT and, as anticipated, inhibited T-induced secretion of PSA and proliferation. However the drug also inhibited DHT-induced PSA secretion and cell proliferation (IC(50) approximately 1 microM). Dutasteride competed for binding the LNCaP cell AR with an IC(50) approximately 1.5 microM. High concentrations of dutasteride (10-50 microM), but not finasteride, in steroi-d-free medium, resulted in enhanced cell death, possibly by apoptosis. Dutasteride reduces cell viability and cell proliferation in both cell lines tested (andro-gen-responsive (LNCaP) and andro-gen-unresponsive (DU145) human prostate cancer (PCa)).in vivo: GG745 has a terminal half-life of approximately 240 hr, and single doses of >10 mg decreased DHT levels significantly more than did single 5-mg doses of finasteride. In placebo treated men without prostate cancer there was an 8.3% median increase in PSA at month 24 compared with -59.5% in those who received dutasteride, using doubled values to correct for dutasteride treatment.Toxicity: Dutasteride may affect male fertility and steroi-d hormone dynamics. Therefore, a 21-day reproduction study was conducted to determine the effects of dutasteride (10, 32 and 100 μg/L) on fish reproduction. Exposure to dutasteride significantly reduced fecundity of fish and affected several aspects of reproductive endocrine functions in both males and females.Clinical trial: Bioequivalence Study Of Dutasteride Five 0.1 mg And One 0.5 mg Soft Gelatin Capsules In Healthy Male Volunteers.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.